C-Rad AB (publ)
CRAD-B.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$931.44M
Close$
$25.81
9.4% downside
Current Fair Value
9.4% downsideOvervalued by 9.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $931.44 Million |
|---|---|
| Enterprise Value | $802.34 Million |
| Dividend Yield | $0.10 (0.34%) |
| Earnings per Share | $0.31 |
| Beta | 0.73 |
| Outstanding Shares | 33,800,000 |
Return
| Return on Equity | 13.62% |
|---|---|
| Return on Assets | 9.80% |
| Return on Invested Capital | 17.44% |
Valuation & Multiples
| P/E Ratio | 19.63 |
|---|---|
| PEG | 3.89 |
| Price to Sales | 2.19 |
| Price to Book Ratio | 2.85 |
| Enterprise Value to Revenue | 1.81 |
| Enterprise Value to EBIT | 12.18 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 17, 2026
EPS Estimate
$0.33
Average shareholder expectationRevenue Estimate
$112.70 M
Average shareholder expectationNext Earnings Call
Expected Date
October 22, 2026
EPS Estimate
$0.30
Average shareholder expectationRevenue Estimate
$102.96 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About C-Rad AB (publ)
98 employees
CEO: Tomas Blomquist C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD,...